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A B S T R A C T
Background
Current guidance suggests that we should monitor the physical health of people with serious mental illness and there has been a
significant financial investment over recent years to provide this.
Objectives
To assess the effectiveness of physical health monitoring as a means of reducing morbidity, mortality and reduction in quality of life in
people with serious mental illness.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (October 2009) which is based on regular searches of CINAHL,
EMBASE, MEDLINE and PsycINFO.
We updated this search October 2012 and added 61 new trials to the awaiting assessment section.
Selection criteria
All randomised or quasi-randomised clinical trials focusing on physical health monitoring versus standard care or comparing i) self
monitoring vs monitoring by health care professional; ii) simple vs complex monitoring; iii) specific vs non-specific checks iv) once
only vs regular checks or v) comparison of different guidance.
Data collection and analysis
The authors (GT, AC, SM) independently screened search results and identified three studies as possibly fulfilling the review’s criteria.
On examination, however, all three were subsequently excluded.
Main results
We did not identify any randomised trials which assessed the effectiveness of physical health monitoring in people with serious mental
illness.
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Authors’ conclusions
There is no evidence from randomised trials to support current guidance and practice. Guidance and practice are based on expert
consensus, clinical experience and good intentions rather than high quality evidence.
Note: the 61 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.
P L A I N L A N G U A G E S U M M A R Y
Physical health care monitoring for people with serious mental illness
In recent years there has been an increasing focus on the physical health of people who suffer frommental illness, it has been recognised
that these individuals are at greater risk of physical health problems for a variety of reasons. There are now a number of different
guidelines telling us how we should monitor physical health in this population. We searched for randomised trials that looked at the
effectiveness of physical health monitoring in preventing deterioration of physical health and maintaining quality of life. Despite the
amount of guidance available we found no relevant studies. Consequently there is no evidence from randomised controlled trials that
physical health monitoring in people with severe mental illness is useful in preventing deterioration in physical health and maintaining
quality of life. This, however, does not mean that physical health monitoring does not affect the physical health of people with severe
mental illness.
B A C K G R O U N D
Description of the condition
The definition of severe mental illness with the widest consensus is
that of theNational Institute ofMentalHealth (NIMH) (Schinnar
1990) and is based on diagnosis, duration and disability (NIMH
1987). People with serious mental illness have conditions such as
schizophrenia or bipolar disorder, over a protracted period of time
resulting in erosion of functioning in day to day life. A European
survey put the total population-based annual prevalence of serious
mental illness at approximately two per thousand (Ruggeri 2000).
As a consequence of their illness people with serious mental illness
have a significantly reduced life expectancy for a variety of rea-
sons including: poor self care, adverse health behaviours (smok-
ing, sedentary lifestyle) and negative effects from psychotropic
medication (weight gain, metabolic syndrome) (Robson 2007). In
schizophrenia, for example, life expectancy is reduced by around
ten years (Newman 1991). A recent publication has shown that
people with schizophrenia have a threefold increase in mortality
compared with the general population of England and Wales, and
that approximately 81% of that increase is from natural causes,
especially cardiovascular disease (Brown 2010). There is histori-
cal evidence that sufferers from serious mental illness also have
increased rates of infectious diseases (including HIV) (Cournos
2005), non-insulin dependent diabetes, respiratory disease and
cancer (Dixon 1999, Robson 2007). Despite this, evidence says
that there exists a lack of physical health monitoring in people
with serious mental illness in both the primary care (Burns 1998)
and in the secondary care setting (Paton 2004).
Description of the intervention
Physical health monitoring can take many forms, and these forms
are highly divergent and dependent on environmental and socioe-
conomic factors. In some instances monitoring is indicated for a
specific group of people because of demographic risk factors; one
such population are those suffering from serious mental illness
(Robson 2007). People with illnesses such as schizophrenia are at
greater risk for a number of conditions. This is compounded by
the fact that they are less likely to seek medical advice and more
likely to be exposed tomedicationswith potentially negative health
consequences (Weinmann 2009). People with serious mental ill-
nesses should stand to benefit greatly from a programme of well
organised and regular physical health monitoring.
Monitoring differs from promotion in that its principle aim is
to obtain information which can then be acted on to treat or
prevent a physical health problem. Promotion, on the other hand,
is the provision of information and encouragement to people in
the hope that they will act to avoid deterioration of current health
or development of future health problems. The effects of physical
health promotion/advice for people with serious mental illness is
evaluated in another future review in this series: Physical health
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advice for people with serious mental illness.
Past reviewers have suggested that “essential routine health monitor-
ing [for people with serious mental illness] should include weight,
body mass index (BMI) and waist circumference, blood pressure, lipid
profiles, screening for insulin resistance and diabetes, dental checks
and eye health checks” (Robson 2007). Physical health care mon-
itoring could, therefore, range from the simplest forms of self-
monitoring, through to more systematised self-screening, to well-
regulated and guideline-directed monitoring of health by health
care professionals.
How the intervention might work
Information obtained fromphysical healthmonitoring is often the
catalyst for more intensive medical input which can be either cura-
tive, palliative or preventative. The routine employment of simple
and relatively inexpensive physical health monitoring has the po-
tential to identify current, and pre-empt future, health problems.
Subsequent action could improve the quality and duration of life
for sufferers of serious mental illness. Additional benefits may in-
clude a reduction in dependence on medical services. “There are
potential savings to be made on prescribing and acute care budgets
through prevention or early detection of serious illness in these groups
of service users” (DoH 2006).
Why it is important to do this review
In August 2006 the UK’s Department of Heath published a com-
missioning framework (DoH 2006) which, based on examples of
current practice (including pilot programmes and expert advice),
was intended to provide best practice guidance on the physical
health needs of people with severe mental illness. In conjunction
with this publication there has been significant investment in 88
English Primary Care Trusts known as ’Spearhead’ Trusts to im-
plement the services it suggested. In addition, a raft of guidance
around physical heath monitoring in psychiatry has arisen over
recent years from organisations such as the Royal College of Psy-
chiatrists (RCPsych 2009; RCPsych 2009a), the National Insti-
tute for Clinical Excellence (NICE 2006), Maudsley Prescribing
Guidelines (Taylor 2009) and the Serious Mental Illness Physical
Health Improvement Profile (White 2009). At no point does the
current commissioning framework or guidance documents refer
to evidence from randomised control trials or previous reviews.
This pathway of identifying a problem, consultation, creation of
guidelines and investment to implement the guidance would ap-
pear to make good sense. We feel that, at this point, it would be
good to assess available evidence of the effects of physical health
monitoring.
O B J E C T I V E S
1. Primary objective
To investigate the effects of the implementation of specific physi-
cal healthcare monitoring compared with standard care in a pop-
ulation suffering from severe mental illness.
2. Secondary objective
To compare types and techniques of monitoring.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials, and eco-
nomic evaluations conducted alongside included randomised con-
trolled trials.We excluded quasi-randomised studies, such as those
allocating by using alternate days of the week. When we encoun-
tered trials described in some way as to suggest or imply that the
study was randomised and where the demographic details of each
group’s participants were similar, we included them and a sensi-
tivity analysis was undertaken to the presence or absence of these
data.
Types of participants
We required that a majority of participants should be within the
age range 18 to 65 years and suffering from severe mental disor-
der preferably as defined by National Institute of Mental Health
(NIMH 1987) but in the absence of that, from diagnosed illness
such as schizophrenia, schizophrenia-like disorders, bipolar disor-
der, or serious affective disorders. We did not consider substance
abuse to be a severe mental disorder in its own right, however
we did feel that studies should remain eligible if they dealt with
people with dual diagnoses, that is those with severe mental ill-
ness plus substance abuse. We did not include studies focusing on
dementia, personality disorder and mental retardation as they are
not covered by our definition of severe mental disorder.
Types of interventions
1. Physical health care monitoring
1.1 General physical health care monitoring in addition to stan-
dard care: monitoring can be any means of observation, supervi-
sion, keeping under review or measuring or testing at intervals.We
defined ’physical health’ as ’soundness of body’ as opposed to the
world health organisation’s definition of ’health’ which includes
mental and social well being (WHO 1948).
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1.2 Focused physical health care monitoring: adherent to specific
guidance e.g. as a result of an identified illness (blood sugar in
diabetes) or as a result of pharmacological treatment (weight gain
with atypical antipsychotic), in addition to standard care.
2. Standard care
Care in which physical health monitoring is not specifically em-
phasised above and beyond care that would be expected for people
not suffering from severe mental illness.
3. Variations in delivery
We feel that there may be important studies comparing different
types of monitoring delivered in several ways. We are interested
in these studies and will endeavour to include them in a relevant
comparison.
3.1 Differences in who undertakes the monitoring - self monitor-
ing vs monitoring by health care professional.
3.2 Differences in complexity of monitoring - simple routine
check/test vs complex check/test.
3.3 Differences in focus of checks - specific health check vs non-
specific health check.
3.4 Differences in pattern of checking - once only checks vs regular
checks.
3.5 Differences in guidance followed - one set of guidelines vs
another.
Types of outcome measures
For the purposes of this review outcomes we divided outcomes
into four time periods, i. immediate (within one week) ii. short
term (one week to six months) iii. medium term (six months to
one year) and, iv. long term (over one year).
Primary outcomes
1. Physical health - immediate
1.1 Failure to identify a disease state and provide appropriate treat-
ment
1.2 Failure to effectively manage a known disease state
1.3 Failure to act on known risk factors
1.4 Unchecked adverse effects of treatment
2. Quality of life
2.1 Loss of independence
2.2 Loss of Activities of Daily Living (ADL) skills
2.3 Chronic pain
2.4 Immobility
2.5 Loss of earnings
2.6 Loss of social status
2.7 Healthy days
Secondary outcomes
1. Physical health - periods other than immediate
1.1 Failure to identify a disease state and provide appropriate treat-
ment
1.2 Failure to improve management of a known disease state
1.3 Failure to act on known risk factors
1.4 Unchecked side-effects of treatment
2. Adverse event
2.1 Number of participants with at least one adverse effect.
2.2 Clinically important specific adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
2.3 Average endpoint in specific adverse effects
2.4 Average change in specific adverse effects
2.5 Death - natural or suicide
3. Service use
3.1 Hospital admission
3.2 Emergency medical treatment
3.3 Use of emergency services
4. Financial dependency
4.1 Claiming unemployment benefit
4.2 Claiming financial assistance because of a physical disability
5. Social
5.1 Unemployment
5.2 Social Isolation as a result of preventable incapacity
5.3 Increased burden to caregivers
6. Quality of life/satisfaction with treatment
6.1 No clinically important change in general quality of life
6.2 Average endpoint general quality of life score
6.3 Average change in general quality of life score
6.4 No clinically important change in general functioning
6.5 Average endpoint general functioning score
6.6 Average change in general functioning score
7. Economic
7.1 Increased costs of health care
7.2 Days off sick from work
7.3 Reduced contribution to society
7.4 Family claiming carers’ allowance
8. Leaving the studies early (any reason, adverse events, inefficacy
of treatment)
9. Global state
9.1 No clinically important change in global state (as defined by
individual studies)
9.2 Relapse (as defined by the individual studies)
10. Mental state (with particular reference to the positive and
negative symptoms of schizophrenia)
10.1 No clinically important change in general mental state score
10.2 Average endpoint general mental score
10.3 Average change in general mental state score
10.4Noclinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
10.5 Average endpoint specific symptom score
10.6 Average change in specific symptom score
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Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group Trials Register (October 2009)
The register was searched using the phrase:[(*physical* or *cardio*
or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or
*Smok* or *sex* or *medical* or *dental* or *alcohol* or *oral* or
*vision* or *sight*or *hearing* or *nutrition* or *advice* or *mon-
itor* in title of REFERENCES) AND (*education* OR *health
promot* OR *preventi* OR *motivate* or *advice* or *monitor*
in interventions of STUDY)]
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major databases, handsearches of relevant
journals and conference proceedings (see Group Module). Incom-
ing trials are assigned to relevant existing or new review titles.
2. TheTrials SearchCo-ordinator, SamanthaRoberts, searched the
Cochrane Schizophrenia Group Trials Register register (October
2012) using the phrase:
[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or
*AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental*
or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutri-
tion* or *advice* or *monitor* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate*
or *advice* or *monitor* in interventions of STUDY)]
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major databases, handsearches of relevant
journals and conference proceedings (see Group Module). Incom-
ing trials are assigned to relevant existing or new review titles.
Searching other resources
1.Unsystematic Search
Weundertookunsystematic searches of a sample of the component
databases (BNI, CINHAL, EMBASE, MEDLINE and Psych-
INFO) to determine if any material may have been overlooked.
We searched using specific phrases (’physical health’, ’monitor-
ing’ and ’mental illness’) as the searches that create the Cochrane
Schizophrenia Group’s register of trials are methodology specific.
We did not identify any relevant trials.
2. Reference Searching
We inspected the references of all identified studies for other rele-
vant studies.
3. Personal Contact
We contacted the first author of each included for information
regarding unpublished trials.
Data collection and analysis
Selection of studies
Authors GT, AC and SM screened the results of the electronic
search. MB inspected a random sample of these results, compris-
ing 10% of the total. The principal reviewer GT and co-reviewer
AC inspected all abstracts of studies identified through screen-
ing and identified potentially relevant reports. Where disagree-
ment occurred we resolved this by discussion, and where there was
still doubt, we acquired the full article for further inspection. We
then requested the full articles of relevant reports for reassessment
and carefully inspected them for a final decision on inclusion (see
Criteria for considering studies for this review). In turn GT and
AC inspected all full reports and independently decided whether
they met inclusion criteria. We were not blinded to the names of
the authors, institutions or journal of publication. Where difficul-
ties or disputes arose, we asked author MB for help and if it was
impossible to decide, these studies were added to those awaiting
assessment and the authors of the papers contacted for clarifica-
tion.
Data extraction and management
1. Extraction
Authors GT and AC independently extracted data from included
studies. Again, we discussed any disagreement, documented our
decisions and, if necessary, we contacted the authors of studies for
clarification. With remaining problems MB helped clarify issues
and we documented our final decisions. We extracted data pre-
sented only in graphs and figures whenever possible, we only in-
cluded it if two reviewers independently had the same result. We
made attempts to contact authors through an open-ended request
in order to obtain any missing information or for clarification
whenever necessary. Where possible, we extracted data relevant to
each component centre of multi-centre studies separately.
2. Management
2.1 Forms
GT and AC extracted data onto standard, simple forms.
2.2 Data from multi-centre trials
Where possible the authors verified independently calculated cen-
tre data against original trial reports.
3. Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument was not written or modified by one
of the trialists for that particular trial; and
c. themeasuring instrument is either i. a self-report or ii. completed
by an independent rater or relative (not the therapist).
4. Endpoint versus change data
We preferred to use scale endpoint data, which typically cannot
have negative values and is easier to interpret from a clinical point
of view. Change data are often not ordinal and are very problematic
to interpret. If endpoint data were unavailable, we used change
data.
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5. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aim to apply the following
standards to all data before inclusion: (a) standard deviations and
means are reported in the paper or obtainable from the authors;
(b) when a scale starts from the finite number zero, the standard
deviation, when multiplied by two, is less than the mean (as oth-
erwise the mean is unlikely to be an appropriate measure of the
centre of the distribution, (Altman 1996); (c) if a scale starts from
a positive value (such as PANSS which can have values from 30 to
210) the calculation described above will be modified to take the
scale starting point into account. In these cases skew is present if
2SD>(S-S min), where S is the mean score and S min is the mini-
mum score. Endpoint scores on scales often have a finite start and
end point and these rules can be applied. When continuous data
are presented on a scale which includes a possibility of negative
values (such as change data), it is difficult to tell whether data are
skewed or not. We entered skewed data from studies of less than
200 participants in additional tables rather than into an analysis.
Skewed data pose less of a problem when looking at means if the
sample size is large, and we entered skewed data from large sample
sizes into syntheses.
6. Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days
in hospital, (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, efforts were made to convert outcome measures
to dichotomous data. This could be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It was generally
assumed that if there had been a 50% reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale (BPRS, Overall
1962) or the Positive and Negative Syndrome Scale (Kay 1986,
Kay 1987), this could be considered as a clinically significant re-
sponse (Leucht 2005, Leucht 2005a). If data based on these thresh-
olds were not available, we used the primary cut-off presented by
the original authors.
8. Direction of graphs
Where possible, we entered data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
physical health monitoring.
9. Summary of findings table
We anticipate including the following outcomes in a summary of
finding table.
1. Physical health - immediate
1.1 Failure to identify a disease state and provide appropriate treat-
ment
1.2 Failure to effectively manage a known disease state
2. Quality of life
2.1 Loss of Activities of Daily Living (ADL) skills
3. Adverse event
3.1 Clinically important specific adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
3.2 Death - natural or suicide
4. Economic
4.1 Increased costs of health care
5. Social
5.1 Social Isolation as a result of preventable incapacity
Assessment of risk of bias in included studies
Againworking independently, GT,AC andMBassessed risk of bias
using the tool described in the Cochrane Collaboration Hand-
book (Higgins 2008). This tool encourages consideration of how
the sequence was generated, how allocation was concealed, the
integrity of blinding at outcome, the completeness of outcome
data, selective reporting and other biases. We would have excluded
studies where allocation was clearly not concealed.
We did not include trials with high risk of bias (defined as at least
3 out of 5 domains were categorised as ’No’) in the meta-analysis.
If the raters disagreed, the final rating was made by consensus with
the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of
trials are provided, we contacted the authors of the studies in
order to obtain further information. Non-concurrence in quality
assessment was reported.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
random-effect risk ratio (RR) and its 95%confidence interval (CI).
It has been shown that RR is more intuitive (Boissel 1999) than
odds ratios and that odds ratios tend to be interpreted as RR by
clinicians (Deeks 2000). Within the Summary of Findings table
we assumed for calculation of the low risk groups that the lowest
control risk applied to all data.We did the same for the assumption
of the highest risk groups. We used the Summary of Findings table
to calculate absolute risk reduction for primary outcomes.
2. Continuous data
2.1 Summary statistic
For continuous outcomes we estimated a fixed-effect mean dif-
ference between groups. We preferred not to calculate effect size
measures (standardised mean difference SMD). However, in the
case of where scales were of such similarity to allow presuming
there was a small difference in measurement, we calculated it and,
whenever possible, we transformed the effect back to the units of
one or more of the specific instruments.
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Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby p values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997, Gulliford
1999).
Where clustering is not accounted for in primary studies, we pre-
sented data in a table, with a (*) symbol to indicate the presence of
a probable unit of analysis error. In subsequent versions of this re-
view we will seek to contact first authors of studies to obtain intra
class correlation co-efficient of their clustered data and to adjust
for this by using accepted methods (Gulliford 1999). Where clus-
tering had been incorporated into the analysis of primary studies,
we present these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra class correlation co-efficient (ICC)
[Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was
not reported it was assumed to be 0.1 (Ukoumunne 1999).
If cluster studies has been appropriately analysed taking into ac-
count intra class correlation co-efficient and relevant data docu-
mented in the report, synthesis with other studies would have been
possible using the generic inverse variance technique.
2. Cross-over trials
Amajor concern of cross-over trials is the carryover effect. It occurs
if an effect (e.g. pharmacological, physiological or psychological) of
the treatment in the first phase is carried over to the second phase.
As a consequence on entry to the second phase the participants
can differ systematically from their initial state despite a wash-out
phase. For the same reason cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
effects are very likely in severe mental illness, we only used data of
the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if rele-
vant, we presented the additional treatment arms in comparisons.
Where the additional treatment arms were not relevant, we did
not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow up data must lose credibility (Xia
2009). For any particular outcome should than 50% of data be
unaccounted, we did not reproduce these data or use them within
analyses. If, however, more than 50% of those in one arm of a
study were lost, but the total loss was less than 50%, we marked
such data with ’*’ to indicate that such a result may well be prone
to bias.
2. Binary
In the case where attrition for a binary outcome is between 0 and
50% and where these data were not clearly described, we presented
data on a ’once-randomised-always-analyse’ basis (an intention to
treat analysis). Those lost to follow up were all assumed to have the
same rates of negative outcome as those who completed, with the
exception of the outcome of death. A sensitivity analysis was un-
dertaken testing how prone the primary outcomes were to change
when ’completed’ data only were compared to the intention to
treat analysis using the above assumption.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0
and 50% and completer-only data were reported, we have repro-
duced these.
3.2 Standard deviations
Where there are missing measures of variance for continuous data
but exact standard error and confidence interval are available for
group means , either ‘p’ value or ’t’ value are available for differ-
ences in mean, we calculated standard deviation value according
to method described in Section 7.7.3 of the Cochrane Handbook
(Higgins 2008). If standard deviationswere not reported and could
not be calculated from available data, we asked authors to supply
the data. In the absence of data from authors, the mean standard
deviation from other studies was used.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results. Therefore, where LOCF data has been used in the trial, if
less than 50% of the data had been assumed, we reproduced these
data and indicated that they are the product of LOCFassumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
To judge clinical heterogeneity, we considered all included studies,
initially without seeing comparison data. We simply inspected all
studies for clearly outlying situations or people which we had not
predictedwould arise. Should such situations or participant groups
arise these will be fully discussed.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise. Should such methodological outliers
arise these will be fully discussed.
3. Statistical
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3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I-squared statistic
Heterogeneity between studies was investigated by considering the
I-squared method alongside the Chi2 ’p’ value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I
2 depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. ’p’ value from Chi2 test, or a
confidence interval for I2).
I2 estimate greater than or equal to 50% accompanied by a sta-
tistically significant Chi2 statistic, was interpreted as evidence of
substantial levels of heterogeneity (Section 9.5.2 - Higgins 2008)
and reasons for heterogeneity were explored. If the inconsistency
was high and the clear reasons were found, we presented data sep-
arately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook
(Higgins 2008). We are aware that funnel plots may be useful in
investigating reporting biases but are of limited power to detect
small-study effects. We did not use funnel plots for outcomes
where there were ten or fewer studies, or where all studies were of
similar sizes. In other cases, where funnel plots were possible, we
sought statistical advice in their interpretation.
Data synthesis
Where possible we employed a random-effect model for analyses.
We understand that there is no closed argument for preference for
use of fixed or random-effect models. The random-effect method
incorporates an assumption that different studies are estimating
different, yet related, intervention effects. According to our hy-
pothesis of an existing variation across studies, to be explored fur-
ther in themeta-regression analysis despite being cautious that that
random-effects methods does put added weight onto the smaller
of the studies - we favoured using random-effect model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipate no sub-group analyses.
2. Investigation of heterogeneity
2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity be
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
2.2 Anticipated heterogeneity
We are concerned that focused physical health care monitoring
may have different effects than amore general approach.We there-
fore anticipate some heterogeneity for the primary outcomes and
propose to summate all data but also present them separately.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they are de-
scribed in some way as to imply randomisation. For the primary
outcomes we included these studies and if there was no substan-
tive difference when we added the implied randomised studies to
those with better description of randomisation, we then employed
all data from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regarding people lost to follow
up (seeDealingwithmissing data) we compared the findings of the
primary outcomes where we used our assumption and compared
with completer data only. If there was a substantial difference, we
reported results and discussed them but continue to employ our
assumption.
R E S U L T S
Description of studies
See: Characteristics of excluded studies; Characteristics of studies
awaiting classification.
Results of the search
The initial search of the Cochrane Schizophrenia Group’s register
of trials in 2009was a combined search designed to identify studies
which would be relevant to this review, and to another sister review
on physical health advice for people with serious mental illness
(Tosh 2010). The search identified 2382 references (from 1558
studies). After examining the reports, only three were suitable for
further examination and all were excluded.Despite the fact that the
Cochrane SchizophreniaGroup’s register of trials is compiled from
large comprehensive and systematic searches for trials, we under-
tookunsystematic searches of a sample of the component databases
(BNI, CINHAL, EMBASE, MEDLINE and PsychINFO) to de-
termine if any material may have been overlooked. We searched
using specific phrases (’physical health’, ’monitoring’ and ’men-
tal illness’) as the searches that create the Cochrane Schizophre-
nia Group’s register of trials are methodology specific. We did not
identify any further relevant trials.
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Included studies
No studies met the criteria for this review.
Excluded studies
One trial was excluded, on the basis that it is an ongoing trial
in the recruitment stage which is focusing on the monitoring of
mental health parameters and not physical health (Jürgens 2008).
Another was excluded as it monitored the effects of a pharmaco-
logical intervention on a physical health parameter (Lan 2007).
The third exclusion was on the basis that the trial compared the
effects of different ways of monitoring a specific anxiety symptom,
and did not look at a physical health (Rostow 1980). For details
please see Characteristics of excluded studies.
1. Awaiting assessment
Sixty one studies are awaiting assessment.
2. Ongoing studies
We are not aware of any ongoing studies.
Risk of bias in included studies
There were no studies that fulfilled the criteria for inclusion. We
did not exclude any studies on the grounds of poor methodology.
Allocation
No studies met the criteria for this review.
Blinding
No studies met the criteria for this review.
Incomplete outcome data
No studies met the criteria for this review.
Selective reporting
No studies met the criteria for this review.
Other potential sources of bias
There were no studies that fulfilled the criteria for inclusion. We
did not exclude any studies on the grounds of poor methodology.
Effects of interventions
Currently we know of no randomised studies describing the effects
of monitoring physical health care of people with serious mental
illnesses.
D I S C U S S I O N
Summary of main results
1. No trial-based evidence
Current medical practice in the UK is led by guidance from bod-
ies such as the National Institute of Clinical Excellence (NICE
2006) and The Maudsley Prescribing Guidelines (Taylor 2009)
who predominantly base their guidance on little more than anec-
dotal evidence, consensus of opinion (Marder 2004) and good in-
tentions. The association between schizophrenia and poor phys-
ical health is well established (Robson 2007) and, taken at face
value, current guidance seems to make sense. Unfortunately his-
tory is littered with treatments and policies which ’seemed like a
good idea at the time’ but which, with the benefit of hindsight,
were, at best, ineffective and, at worst, resulted in harm. Extreme
examples of well-intentioned treatments could be trepanation for
epilepsy (Adams 1856), ice-pick lobotomies for unruly children
(El-Hai 2008), or radium water for high blood pressure (JAMA
1925).More contemporary andmore subtle is thewide use of oil of
evening primrose oil for many ailments when evidence for efficacy
is poor (Bayles 2009). This could mean that hopes are raised inap-
propriately, and, perhaps other more effective treatments avoided.
When it comes to mental health policy, the early legislation for the
Care Programme Approach in the UK was well intentioned but
ultimately imported a largely wasteful and ineffective package of
care from the US (Marshall 1996, Marshall 1998) at a time when
even those in the US had found it necessary to substantially evolve
the approach into a more effective package (Assertive Outreach).
In more recent times the evidence to support the view that spe-
cialist mental health services such as Dual Diagnosis Teams, Early
Intervention or AssertiveOutreachTeams are more beneficial than
appropriately supported Community Mental Health Teams is not
as strong as would have been originally thought (Ley 2000).
Care, and the time of people with serious mental illness is too
costly to waste on ideas that are not of proven benefit. Vulnerable
people with serious mental illness should surely expect that all
aspects of their care has been subject to some degree of evaluation.
Overall completeness and applicability of
evidence
No studies met the criteria for this review.
Quality of the evidence
The three studies we obtained for closer inspection were not ex-
cluded because of issues of quality. We were just unable to find
any studies that were vaguely relevant, regardless of whether they
were high or poor quality.
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Potential biases in the review process
The search criteria both on the Cochrane Schizophrenia Group
Trials Register (October 2009) and on our unsystematic search
(see: Searching other resources) should have been robust enough to
detect relevant studies. It is possible, however, that we have failed
to identify small studies but we think it unlikely that we would
have missed large trials. Studies published in languages other than
English, and those with equivocal results, are often difficult to find
(Egger 1997). Our search was biased by use of English phrases.
However, given that the Cochrane Schizophrenia Group’s Regis-
ter covers many languages but is indexed in English we feel that
this would not have missed many studies within the register. For
example, the search uncovered 101 studies for which the title was
only available in Chinese characters. These were checked for rel-
evance by a Chinese speaking colleague (Jun Xia) and none were
identified as possibly relevant to this review.
Agreements and disagreements with other
studies or reviews
The only other similar systematic review that we are aware of is
Bradshaw 2005. This reports on efficacy of healthy living inter-
ventions for people with schizophrenia. They too identified no
trials of monitoring. We agree with Bradshaw 2005 that rigorous
studies are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Due to the lack of evidence for the current guidance based physical
health monitoring it is important that people with schizophrenia
expect clinicians to explain their intentions clearly. It would seem
reasonable that people with schizophrenia are given the choice of
whether they want to be monitored in this way or, whether they
would want to add to the body of evidence, one way or another, by
being part of a well designed trial from which outcomes relevant
to their care would be derived.
2. For clinicians
Clinicians should be aware that current guidance on monitoring
the physical health for people with serious mental illness is not
supported by any evidence from randomised controlled trials. It
would seem reasonable that this is explained to people with serious
mental illness. It is possible clinicians are expending much effort,
time and financial expenditure on monitoring the physical health
of people with serious mental illnesses which is unnecessary, in-
trusive and costly. Clinicians should, therefore, take a much more
critical view of current guidance and attempt to initiate or get in-
volved with any studies which could provide an evidence-base for
this practice.
3. For policy makers or managers
Current policies and guidelines are bornout of good intentions and
“the evidence for such interventions remains uncertain” (NICE
2006). This puts policy makers in a difficult position galvanising
consensus rather than evidence. There remains an enduring con-
cern that “L’enfer est plein de bonnes volontés ou désirs” [Hell is
full of good intentions or wishes] (St. Bernard of Clairvaux 1150
quoted in Ammer 2003). Policy makers or managers should be
better at recommending active research interest in this area.
4. Note: the 61 citations in the awaiting classification section of
the review may alter the conclusions of the review once assessed.
Implications for research
1. General
We could not identify any randomised trials that assessed the ef-
fectiveness of physical health monitoring in people with serious
mental illness which contradicted the view that current guidance
and practice is based on good intentions and expert opinion. Bas-
ing care on solely evidence from trials is not realistic (Tanenbaum
2005 and Cooper 2003), however,many treatments or approaches
that are not well-evaluated are given to people, when it is actually
entirely possible to evaluate these approaches. Health care profes-
sionals may be doing far more good than they realise - or far more
harm. As part of a duty of care, we argue, that ’what could be
known, should be known’.
2. Specific
We realise that much thought and care goes into the design of
randomised studies. We have, however, also given this issue some
consideration and suggest what we think to be a feasible design
see Additional tables (Table 1).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Jürgens 2008 Allocation: randomised.
Participants: people diagnosed with schizophrenia.
Intervention: genotype monitoring versus intense clinical monitoring, not focusing on physical health
Lan 2007 Allocation: randomised.
Participants: people diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Intervention:monitoring of the effect of aripiprazole and aripiprazole plus haloperidol on prolactin levels, not focusing
on physical health
Lan 2008 Allocation: randomised.
Participants: people diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Intervention:monitoring of the effect of aripiprazole and aripiprazole plus risperidone on prolactin levels, not focusing
on physical health
Rostow 1980 Allocation: randomised.
Participants: people with “compulsive or persistent pacing”, not necessarily having a diagnosis of serious mental
illness
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Suggested design of study
Methods Allocation: randomised, clearly described.
Blinding: single - particular to specific outcomes (see below).
Duration: 6 months.





Interventions 1. General physical health care checklist (e.g. Physical Health Improvement Profile see White 2009): administered
by Care Co-ordinator. N=150.
2. Specific aspect of physical health care checklist (e.g. BSDH 2000): administered by Care Co-ordinator. N=150.
3. Standard care: administered by Care Co-ordinator. N=150.
Outcomes Death.
Morbidity: serious/minor, categorised by type, rates of events - general or specific.
Healthy days.
Service use: visit to heath care practitioner.
Acceptability of checklist.
Compliance: with physical health care advice, including treatments.
Adverse effects: any.
Notes * For 20% difference between groups for a binary outcome to be highlighted with reasonable degree of confidence
150 people are needed per group
WH A T ’ S N E W
Last assessed as up-to-date: 18 January 2010.
Date Event Description
17 October 2012 Amended Update search of Cochrane Schizophrenia Group’s Trial Register (see Search methods for
identification of studies), 61 studies added to awaiting classification.
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H I S T O R Y
Protocol first published: Issue 1, 2010
Review first published: Issue 3, 2010
Date Event Description
17 March 2010 Amended Amendment of outcomes to be included in summary of findings table
17 March 2010 Amended Previously combined studies split into separated studies and included in Excluded Studies section
C O N T R I B U T I O N S O F A U T H O R S
Graeme Tosh - project initiation, protocol writing, primary reviewer, results and discussion writing.
Andrew Clifton - co-reviewer and liaison on discussion and results writing.
Shereen Mala - co-reviewer, liaison on protocol.
Mick Bachner - co-reviewer, screened results of electronic search.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Nottingham, UK.
External sources
• National Institute for Health Research (CLAHRC), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Subsequent to the publication of the protocol we identified that our search strategy may have excluded some relevant studies so we
added the words ’advice’ and ’monitor’ in the title of references section and added *advice* and *monitor* to the interventions of study
field.
The original search phrase: [(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex*
or *medical* or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate* in interventions of STUDY)] yielded 2326 references whilst the new
search phrase :[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex* or *medical*
or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or *monitor* in title of REFERENCES)
AND (*education* OR *health promot* OR *preventi* OR *motivate* or *advice* or *monitor* in interventions of STUDY)] yielded
2383 references.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Health Status; ∗Quality of Life; Disease Progression; Mental Disorders [∗complications]
MeSH check words
Humans
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